Home Alzheimer’s Disease Eric Jonasch, MD, Discusses Use of MK-6482 in VHL Disease–Associated Kidney Cancer

Eric Jonasch, MD, Discusses Use of MK-6482 in VHL Disease–Associated Kidney Cancer

Treatment with MK-6482 appeared to be well tolerated and induced clinical responses among patients with von Hippel-Lindau disease (VHL)–associated renal cell carcinoma (RCC), according to study findings presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program.

The trial showed an objective response rate (ORR) in RCC tumors per RECIST by independent review of 27.9%. Moreover, 8 patients who had an unconfirmed response showed an ORR of 41.0%. Additionally, 86.9% of patients had a decrease in the size of their target lesions and median time to response was 5.5 months.

Eric Jonasch, MD, professor of genitourinary medical oncology at The University of Texas MD Anderson Cancer Center, spoke to CancerNetwork about the results of the trial.

 

Transcription:

So, VHL disease at this time does not have an FDA approved therapy. It’s a hereditary…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Parasite found in undercooked meat linked with risk of rare brain cancer

submitted by /u/Meat_Mithkabob Continue Reading to the Source

Living up to expectations : braincancer

Hey everyone!I wrote a little something about some of the comments you often hear from others and how sometimes you feel like you need...

My Brain Tumor Taught Me To Shift My Perspective on These 5 Things

submitted by /u/andrewjoegeorge Continue Reading to the Source

Recent Comments